<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01757132</url>
  </required_header>
  <id_info>
    <org_study_id>PAS-01</org_study_id>
    <nct_id>NCT01757132</nct_id>
  </id_info>
  <brief_title>Post-Approval Study of the Implantable Miniature Telescope</brief_title>
  <acronym>PAS-01</acronym>
  <official_title>Post-approval Study of VisionCare's Implantable Miniature Telescope (by Dr. Isaac Lipshitz) in Patients With Bilateral Severe to Profound Central Vision Impairment Assoc. With End-stage Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VisionCare, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VisionCare, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the PAS-01 study is to assess the safety of the intraocular as measured by
      the cumulative incidence of patients who within 5 years after implantation experience
      persistent vision-impairing corneal edema (corneal edema leading to persistent loss of best
      corrected distance visual acuity &gt;2 lines from pre-surgery baseline level).

      The study will test the null hypothesis that the percentage of patients who experience
      persistent vision-impairing corneal edema is &gt;17% against the alternative that the percentage
      is &lt;17%. The null hypothesis will be rejected if the upper bound of the two-sided 95%
      confidence integral for the observed percentage is &lt;17%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ECD sub-study. At investigative sites participating in the ECD Sub-Group study, corneal
      endothelial cell density will be measured by non-contact specular microscopy in a subgroup of
      150 patients enrolled in the IMT-PAS-01 in the eye schedule for and implanted with the
      intraocular telescope at study entry, 3 months, 12, months, 24 months, 36 months, 48 months
      and 60 months.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term safety study of implantable miniature telescope</measure>
    <time_frame>5 years after implantation</time_frame>
    <description>Number of persistent vision impairing corneal edema adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">770</enrollment>
  <condition>AMD</condition>
  <arm_group>
    <arm_group_label>Implantable Miniature Telescope</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Post approval study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Miniature Telescope</intervention_name>
    <description>Device - Implantable Miniature Telescope</description>
    <arm_group_label>Implantable Miniature Telescope</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable severe (BVDCA of 10/160 or poorer) to profound (BCDVA of 20/800 or better)
             vision impairment caused by bilateral central scotomas associated with end-stage
             age-related macular degeneration.

          -  65 years of age or older

          -  retinal findings of geographic atrophy or disciform scar with foveal involvement

          -  visually significant cataract

          -  agree to undergo pre- and post-surgery training and assessment

          -  achieve at least a 5-letter improvement with external telescope

          -  have adequate peripheral vision in the eye not scheduled for surgery

        Exclusion Criteria:

          -  Stargardt's macular dystrophy

          -  Anterior chamber depth &lt; 3.0mm

          -  Presence of corneal guttate

          -  Do not meet minimum age and endothelial cell density requirements

          -  evidence of CNV or treatment of CNV within the past 6 months

          -  cognitive impairment that would interfere with ability to understand and complete
             Acceptance of Risk and Informed Decision Agreement or prevent proper
             training/rehabilitation

          -  previous intraocular or cornea surgery of any kind in operative eye, including any
             type of surgery for either refractive or therapeutic purposes or who have prior or
             expected ophthalmic related surgery within 30 days preceding intraocular telescope
             surgery

          -  history of steroid-responsive rise in intraocular pressure, uncontrolled glaucoma, or
             preoperative IOP &gt;22 mm Hg while on maximum medication

          -  known sensitivity to post-operative medications

          -  history of eye rubbing or an ocular condition that predisposes eye rubbing

          -  myopia &gt;6.0 D

          -  hyperopia &gt;4.0D

          -  axial length &lt;21mm

          -  narrow angle, i.e., &lt;Schaffer grade 2

          -  cornea stromal or endothelian dystrophies, including guttate

          -  inflammatory ocular disease

          -  zonular weakness/instability of crystalline lens, or pseudoexfoliation

          -  diabetic retinopathy

          -  untreated retinal tears

          -  retinal vascular disease

          -  optic nerve disease

          -  history of retinal detachment

          -  intraocular tumor

          -  retinitis pigmentosa
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver D Schein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona, LTD</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnet, Dulaney, Perkins Eye</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health Care</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialty Eye Care (Glaucoma Consultants of Colorado)</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Eye Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Eye Care and Laser Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Eye Care</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pepose Vision Institute</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silverstein Eye Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants Of Long Island</name>
      <address>
        <city>Lynbrook</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye &amp; Ear</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreous Retina Macula Consultants of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fine, Hoffman &amp; Packer</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, Storm Eye Institute</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Austin Eye</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78738</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John A. Moran Eye Center, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vistar Eye Center</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2012</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

